IRIS
CARLOMAGNO, FRANCESCA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 3.069
EU - Europa 2.814
NA - Nord America 2.720
SA - Sud America 491
AF - Africa 76
OC - Oceania 4
Continente sconosciuto - Info sul continente non disponibili 2
Totale 9.176
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.581
SG - Singapore 1.768
RU - Federazione Russa 1.217
IT - Italia 722
CN - Cina 594
BR - Brasile 401
HK - Hong Kong 279
VN - Vietnam 229
DE - Germania 195
UA - Ucraina 143
FI - Finlandia 142
CA - Canada 97
IE - Irlanda 94
GB - Regno Unito 90
IN - India 61
NL - Olanda 54
FR - Francia 40
AR - Argentina 35
BD - Bangladesh 32
SE - Svezia 30
PL - Polonia 24
ZA - Sudafrica 24
CI - Costa d'Avorio 22
MX - Messico 22
ES - Italia 17
IQ - Iraq 16
JP - Giappone 16
CO - Colombia 14
EC - Ecuador 12
AT - Austria 11
ID - Indonesia 11
LT - Lituania 10
KR - Corea 8
VE - Venezuela 8
TR - Turchia 7
CL - Cile 6
PY - Paraguay 6
AZ - Azerbaigian 5
PH - Filippine 5
AU - Australia 4
GE - Georgia 4
HN - Honduras 4
JM - Giamaica 4
KE - Kenya 4
MA - Marocco 4
PK - Pakistan 4
AL - Albania 3
BO - Bolivia 3
IL - Israele 3
OM - Oman 3
PA - Panama 3
TN - Tunisia 3
UY - Uruguay 3
UZ - Uzbekistan 3
BA - Bosnia-Erzegovina 2
BE - Belgio 2
BY - Bielorussia 2
CH - Svizzera 2
CR - Costa Rica 2
CZ - Repubblica Ceca 2
DZ - Algeria 2
EG - Egitto 2
EU - Europa 2
GR - Grecia 2
GT - Guatemala 2
HR - Croazia 2
JO - Giordania 2
KZ - Kazakistan 2
LU - Lussemburgo 2
MY - Malesia 2
NP - Nepal 2
PE - Perù 2
RO - Romania 2
TH - Thailandia 2
AD - Andorra 1
AE - Emirati Arabi Uniti 1
AO - Angola 1
BB - Barbados 1
BG - Bulgaria 1
BH - Bahrain 1
BJ - Benin 1
CV - Capo Verde 1
DK - Danimarca 1
DO - Repubblica Dominicana 1
GA - Gabon 1
GD - Grenada 1
GN - Guinea 1
GY - Guiana 1
IR - Iran 1
LA - Repubblica Popolare Democratica del Laos 1
LB - Libano 1
LK - Sri Lanka 1
LY - Libia 1
ML - Mali 1
MN - Mongolia 1
MU - Mauritius 1
NE - Niger 1
NG - Nigeria 1
PS - Palestinian Territory 1
RS - Serbia 1
Totale 9.166
Salva come PNG Salva come JPEG
Città #
Singapore 713
Moscow 313
Hong Kong 273
Chandler 236
Naples 208
Ashburn 197
Beijing 193
Jacksonville 145
Santa Clara 122
Millbury 100
Princeton 98
Ho Chi Minh City 88
Los Angeles 84
Napoli 79
Munich 68
Nanjing 66
San Jose 59
Buffalo 58
Boston 54
Ottawa 53
The Dalles 51
Wilmington 50
Hanoi 48
Hefei 47
Amsterdam 44
São Paulo 42
New York 36
Dallas 33
Redondo Beach 31
Nanchang 29
Woodbridge 25
Montreal 24
Helsinki 22
Turku 22
Warsaw 21
Salerno 20
Chicago 19
Des Moines 19
Shenyang 18
Augusta 17
Brooklyn 17
Orem 16
Chennai 15
Hebei 15
Lawrence 15
Nocera Superiore 15
Poplar 15
Rome 15
Shanghai 15
London 14
Rio de Janeiro 14
Tokyo 14
Falls Church 13
Boardman 12
Giugliano in Campania 12
Kronberg 12
Kunming 12
Mexico City 12
Seattle 12
Ann Arbor 11
Atlanta 11
Changsha 11
Houston 11
Manchester 11
Nuremberg 11
Frankfurt am Main 10
Haiphong 10
Milan 10
Tianjin 10
Waldbuttelbrunn 10
Toronto 9
Washington 9
Denver 8
Düsseldorf 8
Guarulhos 8
Hải Dương 8
Johannesburg 8
Kochi 8
Nola 8
San Mateo 8
Stockholm 8
Acerra 7
Belo Horizonte 7
Brasília 7
Charlotte 7
Erbil 7
Jiaxing 7
Ninh Bình 7
Norwalk 7
Phoenix 7
Porto Alegre 7
Redwood City 7
Santa Maria Capua Vetere 7
Biên Hòa 6
Cantù 6
Cleveland 6
Falkenstein 6
Goiânia 6
Hangzhou 6
Mumbai 6
Totale 4.422
Salva come PNG Salva come JPEG
Nome #
Association between DNA methylation profile and malignancy in follicular-patterned thyroid neoplasms 199
NCOA4 links iron bioavailability to DNA metabolism 157
D898_E901 RET Deletion Is Oncogenic, Responds to Selpercatinib, and Treatment Resistance Can Arise Via RET-Independent Mechanisms 150
Identification of Novel Small Molecule Inhibitors of Oncogenic RET Kinase 140
Mechanisms of RET mediated signal transduction 134
The kinase inhibitor PP1 blocks tumorigenesis induced by RET oncogenes 130
Therapeutic strategies to target the receptor tyrosine kinase AXL in thyroid cancer 128
Genetic Alterations in differentiated thyroid cancer:what can be expected for gene expression profiling of thyroid carcinomas 126
NCOA4 Deficiency Impairs Systemic Iron Homeostasis 121
The Insulin Receptor Substrate (IRS)-1 recruits Phosphatidylinositol 3-Kinase to Ret: evidence for a competition between Shc and IRS-1 for the binding to Ret. 120
Fragment-Based Discovery of a Dual pan-RET/VEGFR2 Kinase Inhibitor Optimized for Single-Agent Polypharmacology 119
Targeted activity of the small molecule kinase inhibitor Pz-1 towards RET and TRK kinases 119
NCOA4 inhibits initiation of DNA replication to maintain genome stability 113
Peroxiredoxin-2: A Novel Regulator of Iron Homeostasis in Ineffective Erythropoiesis 113
Bioisosteric discovery of npa101.3, a second-generation ret/vegfr2 inhibitor optimized for single-agent polypharmacology 113
Efficient inhibition of RET/papillary thyroid carcinoma oncogenic kinases by 4-amino-5-(4-chloro-phenyl)-7-(t-butyl)pyrazolo[3,4-d]pyrimidine (PP2). 109
Different mutations of the RET gene cause different human tumoral diseases. 106
BAY 43-9006 inhibition of oncogenic RET mutants 105
ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases 105
The tyrosine kinase inhibitor ZD6474 blocks proliferation of RET mutant medullary thyroid carcinoma cells. 104
NCOA4 transcriptional coactivator inhibits activation of DNA replication origins. 104
Molecular mechanisms of RET activation in human cancer 103
Ret-mediated mitogenesis requires Src kinase activity. 102
Activation of the Erk8 mitogen-activated protein (MAP) kinase by RET/PTC3, a constitutively active form of the RET proto-oncogene. 102
Ret gene fusions in malignancies of the thyroid and other tissues 102
RET ONCOGENE ACTIVATION IN HUMAN THYROID NEOPLASMS IS RESTRICTED TO THE PAPILLARY CANCER SUBTYPE 101
NCOA4 Links Iron Bioavailability to DNA Metabolism 100
Molecular biology of the MEN2 gene 99
Receptor- and non-receptor tyrosine kinases induce processing of the amyloid precursor protein: role of the low-density lipoprotein receptor-related protein. 98
I geni oncosoppressori in "Patologia Generale" IV Ed, Pontieri-Russo-Frati 97
Glial cell line-derived neurotrophic factor differentially stimulates ret mutants associated with the multiple endocrine neoplasia type 2 syndromes and Hirschsprung's disease 96
The different RET-activating capability of mutations of cysteine 620 or cysteine 634 correlates with the multiple endocrine neoplasia type 2 disease phenotype. 96
Ultrasound-induced mechanical damage of cancer cell cytoskeleton causes disruption of nuclear envelope and activation of cGAS-STING 95
Evolutionary conservation of the Eps8 gene and its mapping to human-chromosome 12q23-q24 95
Constitutive and AP20187-induced ret activation in photoreceptors does not protect from light-induced damage 94
Molecular heterogeneity of RET loss of function in Hirschsprung's disease. 91
Molecular mechanism of 17-allylamino-17-demethoxygeldanamycin (17-AAG)-induced AXL receptor tyrosine kinase degradation. 91
Potent mitogenicity of the RET/PTC3 oncogene correlates with its prevalence in tall-cell variant of papillary thyroid carcinoma 89
The pyruvate kinase activator mitapivat reduces hemolysis and improves anemia in a β-thalassemia mouse model 89
Efficient inhibition of RET/papillary thyroid carcinoma oncogenic kinases by 4-amino-5-(4-chloro-phenyl)-7-(t-butyl)pyrazolo[3,4-d]pyrimidine (PP2) 88
BRAF is a therapeutic target in aggressive thyroid carcinoma. 87
Determination of the frequency of the common 657Del5 Nijmegen breakage syndrome mutation in the German population: no association with risk of breast cancer 86
Discovery of N-Trisubstituted Pyrimidine Derivatives as Type I RET and RET Gatekeeper Mutant Inhibitors with a Novel Kinase Binding Pose 86
Comparison of DNA repair protein expression and activities between human fibroblast cell lines with different radiosensitivities 85
The extent of linkage disequilibrium in four populations with distinct demographic histories 84
The molecular basis for RET tyrosine-kinase inhibitors in thyroid cancer 84
Tamoxifen erythroid toxicity revealed by studying the role of nuclear receptor co-activator 4 in erythropoiesis 84
NCOA4-mediated ferritinophagy in macrophages is crucial to sustain erythropoiesis in mice 83
Molecular heterogeneity of RET loss of function in Hirschsprung's disease 81
Tyrosine 1062 of RET-MEN2A mediates activation of Akt (protein kinase B) and mitogen-activated protein kinase pathways leading to PC12 cell survival 81
The Macrophage Nuclear Receptor Coactivator 4 Counteracts Iron-Deficiency Anemia 81
Iron and ferritin modulate MHC Class i expression and NK cell recognition 80
Antitumor effects of ZD6474, a small molecule Vascular Endothelial Growth Factor receptor tyrosine kinase inhibitor, with additional activity against Epidermal Growth Factor. 79
Attacking cancer with molecularly targeted agents 79
RET\PTC activation in human thyroid carcinomas 78
Activation of RET oncogene and thyroid carcinogenesis 77
Different mutations of the RET gene cause different human tumoral diseases. 76
Cloning of the rat tissue inhibitor of metalloproteinases type 2 (TIMP-2) gene: analysis of its expression in normal and transformed thyroid cells. 75
Protein kinase Calpha activation by RET: evidence for a negative feedback mechanism controlling RET tyrosine kinase 73
RET/PTC oncogene activation defines a subset of papillary thyroid carcinomas lacking evidence of progression to poorly differentiated or undifferentiated tumor phenotypes. 73
Signalling of the Ret receptor tyrosine kinase through the c-Jun N-terminal Protein Kinases (JNKs): evidence for a divergence of the ERKs and JNKs pathways induced by Ret 72
Activation of RET as a dominant transforming gene by germline mutatios of MEN2A and MEN2B 71
Molecular mechanisms of RET activation in human cancer. 71
Benzimidazole Analogues and related methods 71
Discovery of pyrazolo-thieno[3,2-d]pyrimidinylamino-phenyl acetamides as type-II pan-tropomyosin receptor kinase (TRK) inhibitors: Design, synthesis, and biological evaluation 71
Functional expression of the CXCR4 chemokine receptor is induced by RET/PTC oncogenes and is a common event in human papillary thyroid carcinomas 70
Ret-mediated mitogenesis requires Src kinase activity. 69
Mutations in the extracellular domain cause RET loss of function by a dominant negative mechanism 69
Involvement of RET oncogene in human tumours: specificity of RET activation to thyroid tumours. 69
The oncogenic activity of RET point mutants for follicular thyroid cells may account for the occurrence of papillary thyroid carcinoma in patients affaected by familial medullary thyroid carcinoma. 68
Regulation of p27Kip1 protein levels contributes to mitogenic effects of the RET/PTC kinase in thyroid carcinoma cells. 67
Molecular mechanisms of RET activation in human neoplasia. 67
Molecular mechanisms of RET activation in human neoplasia 66
Antitumor effects of ZD6474, a small molecule vascular endothelial growth factor receptor tyrosine kinase inhibitor, with additional activity against epidermal growth factor receptor tyrosine kinase 66
Identification of two novel RET kinase inhibitors through MCR-based drug discovery: design, synthesis and evaluation 66
POR Campania FESR SATIN 66
Ret-mediated mitogenesis requires Src kinase activity 65
Central role of RET in thyroid cancer 65
Receptor tyrosine kinases as targets for anticancer therapeutics 64
POINT MUTATION OF THE RET PROTO-ONCOGENE IN THE TT HUMAN MEDULLARY THYROID CARCINOMA CELL LINE 64
Insights into Current Tropomyosin Receptor Kinase (TRK) Inhibitors: Development and Clinical Application 64
Basi molecolari delle nuove terapie: inibitori delle protein-chinasi. 63
Sorafenib inhibits imatinib-resistant KIT and platelet-derived growth factor receptor beta gatekeeper mutants. 63
Drug insight: Small-molecule inhibitors of protein kinases in the treatment of thyroid cancer. 62
Clinical case seminar: in vivo and in vitro characterization of a novel germline RET mutation associated with low-penetrant nonaggressive familial medullary thyroid carcinoma. 61
Protein kinase Calpha activation by RET: evidence for a negative feedback mechanism controlling RET tyrosine kinase. 60
Frequent RET proto-oncogene mutations in multiple endocrine neoplasia type 2A 60
Mitogenic effects of the up-regulation of minichromosome maintenance proteins in anaplastic thyroid carcinoma 59
Antitumor effects of ZD6474, a small molecule vascular endothelial growth factor receptor tyrosine kinase inhibitor, with additional activity against epidermal growth factor receptor tyrosine kinase. 58
Molecular targeting of the RET kinase in thyroid cancer 57
Cloning and molecular characterization of a novel gene strongly induced by the adenovirus E1A gene in rat thyroid cells 57
Ret-mediated mitogenesis requires Src kinase activity. 56
Ret-mediated mitogenesis requires Src kinase activity 56
Identification of RET kinase inhibitors as potential new treatment for sporadic and inherited thyroid cancer. 55
Molecular Mechanism of RET in Human Cancer 54
Receptor tyrosine kinase inhibitors in thyroid cancer. 53
Point mutation of the RET proto-oncogene in the TT human medullary thyroid carcinoma cell line. 53
Protein kinase Calpha activation by RET: evidence for a negative feedback mechanism controlling RET tyrosine kinase 52
Intracellular signaling by RET tyrosine Kynase 49
Molecular Mechianism of RET Activation In Human Neoplasia 49
Totale 8.553
Salva come PNG Salva come JPEG
Categoria #
all - tutte 31.826
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 31.826
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021162 0 0 0 0 0 0 34 13 29 3 73 10
2021/2022600 9 3 17 3 5 20 25 31 103 36 119 229
2022/2023643 123 49 5 52 76 65 10 54 92 60 42 15
2023/2024568 22 93 62 48 44 53 22 54 16 8 110 36
2024/20252.917 162 218 25 25 58 144 355 198 215 307 910 300
2025/20263.335 714 369 536 529 907 220 60 0 0 0 0 0
Totale 9.346